Overcoming MCL-1-driven adaptive resistance to targeted therapies.
Publication
, Journal Article
Wood, KC
Published in: Nat Commun
January 27, 2020
Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Commun
DOI
EISSN
2041-1723
Publication Date
January 27, 2020
Volume
11
Issue
1
Start / End Page
531
Location
England
Related Subject Headings
- Proto-Oncogene Proteins c-bcl-2
- Proto-Oncogene Proteins B-raf
- Myeloid Cell Leukemia Sequence 1 Protein
- Melanoma
- MAP Kinase Signaling System
- Humans
- Drug Resistance, Neoplasm
Citation
APA
Chicago
ICMJE
MLA
NLM
Wood, K. C. (2020). Overcoming MCL-1-driven adaptive resistance to targeted therapies. Nat Commun, 11(1), 531. https://doi.org/10.1038/s41467-020-14392-z
Wood, Kris C. “Overcoming MCL-1-driven adaptive resistance to targeted therapies.” Nat Commun 11, no. 1 (January 27, 2020): 531. https://doi.org/10.1038/s41467-020-14392-z.
Wood KC. Overcoming MCL-1-driven adaptive resistance to targeted therapies. Nat Commun. 2020 Jan 27;11(1):531.
Wood, Kris C. “Overcoming MCL-1-driven adaptive resistance to targeted therapies.” Nat Commun, vol. 11, no. 1, Jan. 2020, p. 531. Pubmed, doi:10.1038/s41467-020-14392-z.
Wood KC. Overcoming MCL-1-driven adaptive resistance to targeted therapies. Nat Commun. 2020 Jan 27;11(1):531.
Published In
Nat Commun
DOI
EISSN
2041-1723
Publication Date
January 27, 2020
Volume
11
Issue
1
Start / End Page
531
Location
England
Related Subject Headings
- Proto-Oncogene Proteins c-bcl-2
- Proto-Oncogene Proteins B-raf
- Myeloid Cell Leukemia Sequence 1 Protein
- Melanoma
- MAP Kinase Signaling System
- Humans
- Drug Resistance, Neoplasm